We have located links that may give you full text access.
Cost-effectiveness of stereotactic core needle biopsy: analysis by means of mammographic findings.
Radiology 1997 March
PURPOSE: To determine the cost savings of stereotactic core needle biopsy over open surgical biopsy in patient subgroups defined according to mammographic findings.
MATERIALS AND METHODS: From July 1992 through February 1995, stereotactic core needle biopsy was performed in 356 women with 405 nonpalpable breast lesions (254 were masses and 151 were calcification). Lesions were classified according to mammographic finding, size, and level of suspicion. Two hundred three lesions were classified as indeterminate, 166 as suspicious, and 36 as highly suspicious. Medicare reimbursements for 1995 were used to determine costs and cost savings.
RESULTS: Overall cost savings for stereotactic core biopsy over open surgical biopsy was $741 per case. Average cost savings per case was $807 for masses and $630 for calcifications. The greatest savings occurred in the cases of indeterminate masses, with an average of $856 saved per case. The least savings occurred in the cases of highly suspicious calcifications, with $446 saved per case.
CONCLUSION: Cost savings of stereotactic core needle biopsy vary in subgroups of patients defined according to mammographic findings. Over-all savings will depend on the distribution of patients among these groups. In this series, cost savings were realized with stereotactic core biopsy over open surgical biopsy for all mammographic subgroups.
MATERIALS AND METHODS: From July 1992 through February 1995, stereotactic core needle biopsy was performed in 356 women with 405 nonpalpable breast lesions (254 were masses and 151 were calcification). Lesions were classified according to mammographic finding, size, and level of suspicion. Two hundred three lesions were classified as indeterminate, 166 as suspicious, and 36 as highly suspicious. Medicare reimbursements for 1995 were used to determine costs and cost savings.
RESULTS: Overall cost savings for stereotactic core biopsy over open surgical biopsy was $741 per case. Average cost savings per case was $807 for masses and $630 for calcifications. The greatest savings occurred in the cases of indeterminate masses, with an average of $856 saved per case. The least savings occurred in the cases of highly suspicious calcifications, with $446 saved per case.
CONCLUSION: Cost savings of stereotactic core needle biopsy vary in subgroups of patients defined according to mammographic findings. Over-all savings will depend on the distribution of patients among these groups. In this series, cost savings were realized with stereotactic core biopsy over open surgical biopsy for all mammographic subgroups.
Full text links
Related Resources
Trending Papers
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app